See more : Silver Lake Ontario Inc. (HRTFF) Income Statement Analysis – Financial Results
Complete financial analysis of Allergy Therapeutics plc (AGYTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allergy Therapeutics plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Shanthi Gears Limited (SHANTIGEAR.BO) Income Statement Analysis – Financial Results
- Icosavax, Inc. (ICVX) Income Statement Analysis – Financial Results
- Interdyne Company (ITDN) Income Statement Analysis – Financial Results
- The Chemours Company (0HWG.L) Income Statement Analysis – Financial Results
- Rexel S.A. (RXEEY) Income Statement Analysis – Financial Results
Allergy Therapeutics plc (AGYTF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.allergytherapeutics.com
About Allergy Therapeutics plc
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.20M | 59.59M | 72.77M | 84.33M | 78.20M | 73.72M | 68.35M | 64.14M | 48.51M | 43.23M | 41.96M | 39.28M | 41.28M | 41.55M | 40.75M | 37.76M | 31.02M | 25.74M | 23.56M | 20.61M | 18.00M | 17.33M | 15.14M |
| Cost of Revenue | 25.46M | 26.34M | 23.26M | 22.11M | 20.20M | 18.38M | 17.01M | 16.77M | 14.07M | 12.18M | 11.95M | 11.95M | 13.67M | 13.22M | 11.16M | 13.56M | 10.87M | 10.07M | 6.51M | 4.85M | 5.51M | 5.33M | 5.27M |
| Gross Profit | 29.74M | 33.25M | 49.51M | 62.23M | 58.00M | 55.34M | 51.33M | 47.37M | 34.44M | 31.05M | 30.00M | 27.33M | 27.61M | 28.33M | 29.59M | 24.19M | 20.16M | 15.67M | 17.05M | 15.75M | 12.49M | 12.00M | 9.87M |
| Gross Profit Ratio | 53.87% | 55.79% | 68.03% | 73.79% | 74.17% | 75.07% | 75.11% | 73.85% | 71.00% | 71.83% | 71.51% | 69.57% | 66.88% | 68.18% | 72.60% | 64.08% | 64.98% | 60.89% | 72.35% | 76.45% | 69.37% | 69.26% | 65.18% |
| Research & Development | 22.90M | 20.12M | 15.66M | 12.89M | 5.85M | 6.95M | 16.02M | 9.30M | 16.22M | 3.12M | 2.96M | 2.54M | 2.10M | 1.67M | 2.21M | 5.30M | 16.30M | 25.34M | 9.56M | 5.62M | 451.00K | 527.00K | 2.54M |
| General & Administrative | 22.79M | 25.18M | 20.83M | 20.67M | 19.63M | 17.60M | 15.54M | 13.78M | 10.09M | 10.22M | 7.99M | 7.85M | 15.18M | -8.29M | -6.03M | -14.74M | -12.71M | -11.14M | -6.81M | -4.96M | -2.23M | 0.00 | 0.00 |
| Selling & Marketing | 19.59M | 23.71M | 26.00M | 25.20M | 24.85M | 27.00M | 27.13M | 26.89M | 20.22M | 17.06M | 17.92M | 16.28M | 17.88M | 17.52M | 16.14M | 14.89M | 12.85M | 11.31M | 9.83M | 8.01M | 6.57M | 0.00 | 0.00 |
| SG&A | 42.38M | 48.88M | 46.83M | 45.87M | 44.48M | 44.59M | 42.68M | 40.67M | 30.32M | 27.28M | 25.91M | 24.12M | 33.06M | 9.23M | 10.12M | 158.00K | 147.00K | 169.00K | 3.03M | 3.05M | 4.34M | 0.00 | 0.00 |
| Other Expenses | -287.00K | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -154.00K | -171.00K | -191.00K | 0.00 | 0.00 | 0.00 | -196.00K | -193.00K | 3.37M | 367.00K | 31.00K | -350.00K | -262.00K | -34.00K | 0.00 | 0.00 |
| Operating Expenses | 64.99M | 72.90M | 61.75M | 58.19M | 49.69M | 50.95M | 58.06M | 49.26M | 46.39M | 30.33M | 28.80M | 26.66M | 35.16M | 28.39M | 28.01M | 32.68M | 44.71M | 50.92M | 24.80M | 18.95M | 10.93M | 13.57M | 14.07M |
| Cost & Expenses | 90.46M | 99.24M | 85.01M | 80.30M | 69.90M | 69.33M | 75.08M | 66.03M | 60.46M | 42.51M | 40.75M | 38.61M | 48.83M | 41.62M | 39.17M | 46.25M | 55.58M | 60.99M | 31.31M | 23.81M | 16.45M | 18.90M | 19.34M |
| Interest Income | 285.00K | 329.00K | 257.00K | 117.00K | 266.00K | 103.00K | 154.00K | 151.00K | 180.00K | 147.00K | 170.00K | 19.00K | 5.00K | 2.00K | 9.00K | 30.00K | 201.00K | 647.00K | 545.00K | 531.00K | 60.00K | 33.00K | 24.00K |
| Interest Expense | 4.11M | 2.44M | 669.00K | 491.00K | 504.00K | 201.00K | 320.00K | 225.00K | 293.00K | 218.00K | 308.00K | 404.00K | 457.00K | 1.54M | 1.79M | 3.24M | 1.97M | 131.00K | 4.00K | 42.00K | 26.00K | 39.00K | 545.00K |
| Depreciation & Amortization | 4.32M | 4.22M | 4.17M | 4.13M | 3.91M | 2.09M | 2.02M | 1.94M | 1.67M | 1.29M | 1.29M | 1.34M | 1.89M | 1.70M | 1.43M | 1.32M | 1.16M | 955.00K | 1.12M | 884.00K | 319.00K | 944.00K | 1.92M |
| EBITDA | -30.74M | -35.10M | -7.82M | 8.28M | 12.49M | 6.58M | -4.56M | 191.00K | -10.56M | 2.17M | 2.68M | 2.03M | 2.99M | 727.00K | 3.10M | -6.89M | -17.11M | -24.67M | -5.38M | -1.00M | 1.94M | 5.24M | -2.31M |
| EBITDA Ratio | -55.69% | -58.91% | -10.75% | 9.82% | 15.97% | 8.93% | -6.67% | 0.30% | -20.83% | 5.01% | 6.35% | 5.17% | 7.24% | 0.70% | 7.19% | -15.11% | -55.17% | -95.76% | -21.40% | -6.11% | 10.75% | 13.49% | -14.93% |
| Operating Income | -35.26M | -39.65M | -12.25M | 4.03M | 8.31M | 4.39M | -6.73M | -1.90M | -11.95M | 725.00K | 1.21M | 668.00K | 1.09M | 115.00K | 1.46M | 5.10M | 15.59M | 26.28M | 6.71M | 2.42M | 1.56M | 1.39M | 4.25M |
| Operating Income Ratio | -63.87% | -66.55% | -16.83% | 4.78% | 10.62% | 5.96% | -9.85% | -2.96% | -24.64% | 1.68% | 2.88% | 1.70% | 2.65% | 0.28% | 3.57% | 13.52% | 50.26% | 102.07% | 28.50% | 11.73% | 8.64% | 8.04% | 28.08% |
| Total Other Income/Expenses | -3.91M | -2.11M | -412.00K | -374.00K | -238.00K | -98.00K | -166.00K | -74.00K | -113.00K | -71.00K | -125.00K | -139.00K | -452.00K | -2.43M | -1.57M | -16.54M | -35.84M | -52.03M | -12.89M | -4.61M | 34.00K | 2.87M | -9.02M |
| Income Before Tax | -39.17M | -41.77M | -12.66M | 3.66M | 8.07M | 4.29M | -6.90M | -1.97M | -12.06M | 654.00K | 1.08M | 432.00K | 640.00K | -2.31M | -116.00K | -11.44M | -20.24M | -25.76M | -6.17M | -2.19M | 1.59M | 4.26M | -4.77M |
| Income Before Tax Ratio | -70.95% | -70.09% | -17.39% | 4.34% | 10.32% | 5.82% | -10.09% | -3.07% | -24.87% | 1.51% | 2.58% | 1.10% | 1.55% | -5.57% | -0.28% | -30.29% | -65.26% | -100.07% | -26.20% | -10.63% | 8.83% | 24.58% | -31.52% |
| Income Tax Expense | 1.05M | 1.31M | 1.12M | 771.00K | 1.01M | 826.00K | 637.00K | 511.00K | 1.01M | 546.00K | 343.00K | -104.00K | -183.00K | 349.00K | -702.00K | 326.00K | 53.00K | -2.50M | -12.87M | -4.56M | 372.00K | -916.00K | -109.00K |
| Net Income | -40.22M | -43.07M | -13.78M | 2.89M | 7.06M | 3.47M | -7.53M | -2.48M | -13.07M | 108.00K | 741.00K | 633.00K | 823.00K | -2.66M | 586.00K | -11.76M | -20.30M | -23.26M | -6.17M | -2.19M | 1.22M | 5.18M | -4.66M |
| Net Income Ratio | -72.86% | -72.28% | -18.93% | 3.42% | 9.03% | 4.70% | -11.02% | -3.87% | -26.95% | 0.25% | 1.77% | 1.61% | 1.99% | -6.41% | 1.44% | -31.16% | -65.43% | -90.34% | -26.20% | -10.63% | 6.77% | 29.87% | -30.80% |
| EPS | 0.00 | -0.06 | -0.01 | 0.00 | 0.01 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.14 | -0.25 | -0.28 | -0.09 | -0.04 | 0.03 | 0.08 | -0.07 |
| EPS Diluted | 0.00 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.14 | -0.25 | -0.28 | -0.09 | -0.04 | 0.03 | 0.08 | -0.07 |
| Weighted Avg Shares Out | 0.00 | 669.84M | 1.40B | 1.39B | 1.38B | 1.37B | 595.10M | 592.19M | 570.34M | 475.20M | 451.54M | 408.39M | 326.80M | 310.76M | 293.14M | 81.99M | 81.95M | 81.95M | 66.12M | 57.47M | 40.94M | 62.95M | 62.95M |
| Weighted Avg Shares Out (Dil) | 0.00 | 670.36M | 1.40B | 1.47B | 1.46B | 1.45B | 595.10M | 592.19M | 570.34M | 498.24M | 471.51M | 427.02M | 340.05M | 323.35M | 305.58M | 81.99M | 81.95M | 81.95M | 66.12M | 57.47M | 49.29M | 62.95M | 62.95M |
Allergy Therapeutics to suspend shares after accounts delay
Allergy Therapeutics shed more than half of its value as it warned that audited results for the year to June 2022 would not be ready by the end of this year. “Consequently, the shares of the company will be suspended...
Allergy Therapeutics doses first patient in 'pivotal' hay fever trial
Allergy Therapeutics said it had dosed its first patient in a phase III trial for a new grass pollen vaccine, while screening is underway for a safety trial of its peanut allergy jab. Grass MATA MPL, Allergy's six-jab allergen-specific immunotherapy...
Allergy Therapeutics plans for UK manufacturing site restart is "welcome news" says finnCap
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) 'house' broker finnCap says news that the company expects to restart production at its UK manufacturing site on 14 November is "welcome news". However, the City broker's analysts noted that the circa 7-week voluntary shut-down...
Allergy Therapeutics to resume UK production in mid-November
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is set to resume operations at its Freeman facility in Worthing, UK from November 14. The AIM-listed biotech company voluntarily paused production following an internal review of its current operating processes as part of a...
Allergy Therapeutics CEO: Temporary production pause will help build capacity for the future growth
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it had temporarily paused production at its Freeman manufacturing facility in Worthing, West Sussex, in order to accelerate site improvements there. The partial stop follows an internal review of current operating processes, investors were...
Allergy Therapeutics raises funds as it gears up for the start of two key clinical trials
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) accompanied full year results with fund-raising plans as it gears up for the start of two key clinical trials in its innovative immunotherapy pipeline. The specialty pharmaceutical company announced a subscription by Southern Fox and...
Allergy Therapeutics looks ahead to start of clinical trials
Allergy Therapeutics said it expects net profits this year to meet net profit forecasts for the year just ended even on reduced revenues. The hay fever and vaccine specialist added revenues for the year to June 2022 will be £72.8mln or...
Allergy Therapeutics to present 18 posters at EAACI conference
Allergy Therapeutics said will present 18 posters and host two symposia at the European Academy of Allergy and Clinical Immunology (EAACI) 2022 this month. These will include further data from preclinical studies demonstrating the potential of its peanut allergy vaccine...
Allergy Therapeutics says CFO to leave
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF)'s chief financial officer has said he plans to leave the company after six years to pursue non-executive roles. Nick Wykeman will leave in six months, giving the business time to recruit a successor.
Allergy Therapeutics to present new data on lead vaccines this week
Allergy Therapeutics PLC (AIM:AGY) said it will publish new data on its three main vaccine developments at the joint WAO & BSACI conference in Edinburgh this week. A poster with data from an exploratory field study ahead of the proposed...
Source: https://incomestatements.info
Category: Stock Reports